Navigation Links
Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone

Interim results in a randomized phase II/III clinical trial anticipated later this year

SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced the publication of preclinical studies, which demonstrate that treatment with pixantrone (BBR 2778) resulted in minimal or no significant cardiotoxicity, while doxorubicin and mitoxantrone induced significant cardiac damage. The studies compared the cardiac side effects of equiactive doses of pixantrone to doxorubicin and mitoxantrone in mice pre-treated with a cardiotoxic dose of doxorubicin as well as in mice without prior treatment. The article was published in the June 2007 journal Investigational New Drugs.

"In preclinical hematological tumor models pixantrone showed higher effectiveness and minimal or lack of cardiotoxicity as compared to mitoxantrone or doxorubicin. The findings reported in this article strongly support the clinical potential of pixantrone as a replacement for currently marketed anthracyclines. We hope our randomized phase II/III RAPID (PIX203) study in first-line aggressive NHL will confirm these preclinical results in patients and possibly diminish the most serious side effect associated with current standard treatments -- irreversible heart damage," said Gabriella Pezzoni, Ph.D., Scientific Director at Cell Therapeutics Europe S.r.l. (Milan).

In spite of their dose-dependent cardiotoxic effects, anthracyclines are still considered the standard of care because of their efficacy in several tumor types, including breast cancer, leukemia, and non-Hodgkin's lymphoma (NHL). Because of the irreversible nature of the cardiac damage that accompanies the use of currently marketed anthracyclines, patients who are treated with these agents are subject to a maximum cumulative life-time dose, which may result in premature discontinuation of therapy and limit the physician's ability to use this active class of a
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2
(Date:7/25/2014)... Stwd.co.uk, one of the leading dress manufacturers ... cheap evening dress for women. In addition, the ... for these items. They are available at discounted rates, ... August 30. , “We are pleased to announce our ... have a large number of stylish special occasion gowns ...
(Date:7/25/2014)... July 25, 2014 Healthpointe is ... clinic is offering Occupational Medicine services to ... happily accepting referrals and workers’ compensation cases. ... Mirada clinic include wound care treatment management, return-to-work ... assessments, pre-employment screening & physicals, and illness and ...
(Date:7/25/2014)... MEDICC announced diplomas went to 1,382 new ... University of Havana’s graduation ceremonies that also included graduates ... the 879 international graduates from 28 countries, 20 were ... Professors and hundreds of parents packed the Cuban labor ... Vice President Ramón Machado Ventura and Minister of Health ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 CMS recently ... health plans for providing inadequate access to prescription drugs. ... to the health and safety of beneficiaries in areas ... coverage determinations, and CMS is taking quick and firm ... Atlantic Information Services webinar, “Avoiding Costly Part D ...
(Date:7/25/2014)... 2014 According to the ... by Vkool.com, this is a comprehensive guide ... some common types of hemorrhoids including:, ... ,     Young children with hemorrhoids , ...     Very large hemorrhoids and chronic hemorrhoids ...
Breaking Medicine News(10 mins):Health News:Famous Supplier Stwd.co.uk Announces Its New Selection of Evening Dresses for Women 2Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:MEDICC Congratulates 20 New MDs for the USA Graduating from Cuba’s Latin American Medical School 2Health News:MEDICC Congratulates 20 New MDs for the USA Graduating from Cuba’s Latin American Medical School 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3
... Parents on How to Help Children Cope, WESTPORT, ... that responds to disasters and works to improve the,lives ... of crisis experts,to assist children and families affected by ... will be posted to San Diego, will provide assistance ...
... People with Diabetes Affected ... by California Wildfires, ALEXANDRIA, Va., ... for people with diabetes who,are affected by the California wildfires. ... supplies to manage their health. 1) Medication and Supplies -- ...
... of children with attention deficit hyperactivity disorder (ADHD) at ... was missing: the fathers., Fabiano, an assistant professor in the ... a graduate assistant at the UB Center for Children ... has helped more than 2,500 children with behavioral, emotional ...
... Fisher,Scientific Inc. (NYSE: TMO ), the world ... ground on a new $17 million (USD) facility ... services in that,country. The facility will focus on ... pharmaceutical samples to,patients participating in clinical trials across ...
... Md., Oct. 23 Martek Biosciences,Corporation (Nasdaq: ... of a,district court in Dusseldorf, Germany, has orally ... company,s patent infringement suit against (i) Lonza,Ltd., (ii) ... Food Ingredients GmbH. In a separate suit against ...
... BOTHELL, Wash., Oct. 23 Cardiac Science,Corporation (Nasdaq: ... cardiac monitoring,and defibrillation products, announced today that it ... Tuesday, October 30, 2007 after the,market close. The ... and,investors for 4:30 p.m. Eastern Time to discuss ...
Cached Medicine News:Health News:Save the Children to Help Youngsters Impacted by California Wildfires 2Health News:Save the Children to Help Youngsters Impacted by California Wildfires 3Health News:Save the Children to Help Youngsters Impacted by California Wildfires 4Health News:Save the Children to Help Youngsters Impacted by California Wildfires 5Health News:Emergency Preparedness for People With Diabetes 2Health News:Getting fathers involved in children's ADHD treatment programs 2Health News:Getting fathers involved in children's ADHD treatment programs 3Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 2Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 3Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4Health News:Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinova's Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements 2Health News:Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinova's Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements 3Health News:Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: